Zevra Therapeutics (NASDAQ:ZVRA) Receives New Coverage from Analysts at Guggenheim

Guggenheim started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report released on Monday, Marketbeat reports. The brokerage issued a buy rating and a $20.00 target price on the stock.

Several other equities analysts have also commented on the stock. Maxim Group upped their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a buy rating in a research report on Tuesday, September 24th. Roth Mkm raised their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a buy rating in a research note on Tuesday, September 24th. Cantor Fitzgerald reiterated an overweight rating on shares of Zevra Therapeutics in a research report on Tuesday, October 1st. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a report on Wednesday, September 18th. Finally, JMP Securities began coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an outperform rating and a $17.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Buy and an average price target of $20.83.

Zevra Therapeutics Trading Down 6.5 %

Zevra Therapeutics stock opened at $7.92 on Monday. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $8.95. The firm’s 50-day moving average is $7.41 and its 200-day moving average is $5.86. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The company has a market cap of $331.48 million, a P/E ratio of -5.87 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period last year, the company posted ($0.15) earnings per share. On average, equities analysts expect that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Thomas Anderson bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was acquired at an average price of $6.81 per share, with a total value of $68,100.00. Following the completion of the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at $136,200. This represents a 100.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. City State Bank raised its position in shares of Zevra Therapeutics by 14.1% during the third quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after purchasing an additional 2,000 shares during the period. SG Americas Securities LLC purchased a new stake in Zevra Therapeutics during the third quarter valued at about $105,000. Sanctuary Advisors LLC acquired a new position in shares of Zevra Therapeutics in the second quarter worth about $474,000. The Manufacturers Life Insurance Company increased its position in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after acquiring an additional 2,452 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. raised its holdings in shares of Zevra Therapeutics by 6.5% during the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after acquiring an additional 28,107 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.